Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
NRG Oncology
Genmab
Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Universität des Saarlandes
Arcus Biosciences, Inc.
AstraZeneca
Washington University School of Medicine
Institut Claudius Regaud
Pfizer
M.D. Anderson Cancer Center
Guangxi Medical University
Incyte Corporation
Gilead Sciences
Rutgers, The State University of New Jersey
Rakuten Medical, Inc.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Groupe Oncologie Radiotherapie Tete et Cou
Zhejiang Provincial People's Hospital
Merck Sharp & Dohme LLC
ALX Oncology Inc.
GERCOR - Multidisciplinary Oncology Cooperative Group
Merck Sharp & Dohme LLC
DEKA Biosciences
University of Chicago
University of Chicago
City of Hope Medical Center
Chengdu University of Traditional Chinese Medicine
Sun Yat-sen University
Hospital of Stomatology, Wuhan University
Institute of Oncology Ljubljana
GlaxoSmithKline
Taiho Pharmaceutical Co., Ltd.
University of Chicago
University of Chicago
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Rutgers, The State University of New Jersey
Shanghai Jiao Tong University School of Medicine
Austrian South Oncology Group
University of Chicago
Shanghai Jiao Tong University School of Medicine
Beijing Tongren Hospital
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
First Affiliated Hospital of Zhejiang University
Presage Biosciences
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Shanghai Henlius Biotech
Zhejiang University